MGO One Seven LLC Purchases 13,017 Shares of Sanofi $SNY

MGO One Seven LLC lifted its position in Sanofi (NASDAQ:SNY) by 44.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,232 shares of the company’s stock after purchasing an additional 13,017 shares during the quarter. MGO One Seven LLC’s holdings in Sanofi were worth $2,047,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Advisory Services Network LLC boosted its stake in Sanofi by 1.4% during the third quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock worth $743,000 after buying an additional 210 shares in the last quarter. Waterfront Wealth Inc. lifted its holdings in shares of Sanofi by 0.4% during the 3rd quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock worth $2,463,000 after acquiring an additional 214 shares during the period. HighPoint Advisor Group LLC lifted its holdings in shares of Sanofi by 2.3% during the 3rd quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock worth $468,000 after acquiring an additional 226 shares during the period. GAMMA Investing LLC boosted its position in shares of Sanofi by 5.5% during the 4th quarter. GAMMA Investing LLC now owns 5,058 shares of the company’s stock valued at $245,000 after acquiring an additional 264 shares in the last quarter. Finally, IFG Advisory LLC increased its stake in Sanofi by 3.1% in the third quarter. IFG Advisory LLC now owns 8,969 shares of the company’s stock valued at $423,000 after acquiring an additional 271 shares during the period. 14.03% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. BNP Paribas Exane lowered Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research note on Monday, April 20th. Argus raised Sanofi to a “strong-buy” rating in a report on Monday, April 27th. UBS Group restated a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th. Finally, Weiss Ratings lowered Sanofi from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 29th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Sanofi currently has an average rating of “Hold” and a consensus target price of $51.00.

Sanofi Price Performance

NASDAQ:SNY opened at $43.31 on Monday. The firm has a market cap of $105.63 billion, a PE ratio of 12.10, a price-to-earnings-growth ratio of 1.07 and a beta of 0.35. Sanofi has a 12 month low of $42.78 and a 12 month high of $53.36. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. The company’s 50-day moving average price is $46.17 and its two-hundred day moving average price is $47.76.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th will be issued a $2.4225 dividend. This represents a dividend yield of 559.0%. The ex-dividend date of this dividend is Monday, May 4th. This is an increase from Sanofi’s previous annual dividend of $2.04. Sanofi’s dividend payout ratio (DPR) is presently 49.44%.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.